Home / Publication / A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

Publication

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

Author(s): Thijs J. Zweers, Jos Lommerse, Eline van Maanen, Manash S. Chatterjee

Year: October 22, 2024

Recommended for you

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

Blog

How Model-informed drug development rescue projects from a risky situation

Case Study

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

Publication

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Webinar

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

How Model-informed drug development rescue projects from a risky situation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Newsletter sign up

Quick links

Solutions

Contact

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

How Model-informed drug development rescue projects from a risky situation​

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Newsletter sign up

Quick links

Solutions

Contact

How Model-informed drug development rescue projects from a risky situation